FirstWord Publishing, June 2010, Pages: 34
and reimbursement policies have traditionally sunk generics company margins in the established markets of the UK, US and Germany, the specialty sector has gone from strength to strength. In 2009, for example, while
GBI Research, May 2012, Pages: 129
data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The global generics market cardiovascular drugs
GBI Research, May 2012, Pages: 129
data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The global generics market cardiovascular drugs
GBI Research, April 2012, Pages: 99
-2012
Table 7: Pricing and Reimbursement in Generics, The US, GenericDrug Cost-Sharing (%), 2011-2020
Table 8: Pricing and Reimbursement in Generics, The UK, Healthcare Expenditure, 2009
Table 9: Pricing
Frost & Sullivan, Dec 2008, Pages: 75
examine the generic pharmaceuticals markets in Italy, Portugal, Spain and France.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service programme
Frost & Sullivan, Dec 2011, Pages: 213
Generic Pharmaceuticals Market – A Global Analysis Time is Ripe for Generics Manufacturers as Key Blockbuster Drugs Set to go Off-patent
The global generic pharmaceuticals market is likely
FirstWord Publishing, Nov 2010, Pages: 54
.
For the generics industry, it heralds a boom-time. In regulated markets, relatively inexpensive genericdrugs are increasingly favoured by payers for their low cost and effectiveness. Prescribed by physicians
Decision Resources, Inc., Oct 2008, Pages: 78
and characterized by aggressive generics erosion. How rapid is price erosion in Germany? How large are price differentials between generics and branded drugs in Germany? How has the United Kingdom’s strong generic
Frost & Sullivan, June 2007, Pages: 72
a detailed analysis of the European generics market in light of various opportunities created by the patent expiry of blockbuster drugs. It includes an overview on generics, market engineering measurements
Spectra Intelligence, Nov 2011, Pages: 66
, on the analysis of diverse therapeutic segments, generic opportunities and on Orphan Drugs. Dr. Norman has extensive experience of the pharmaceutical industry in both R&D and competitive intelligence. His
Global Industry Analysts, Inc., Jan 2012, Pages: 443
and genericdrugs. Pharma companies are also eyeing emerging markets that could offer future growth potential for the companies. However, these measures are largely long-term and carry substantial risks
Frost & Sullivan, July 2011, Pages: 94
to the favouring of the genericdrugs segment, which is expected to boost the growth of the market.
- The focus on biological APIs is also on the rise in western Europe. The advancements in biotechnology
Pharma-Reports, Jan 2012, Pages: 80
of key pharma industry trends. This report offers an analysis of the impact of those trends, and reforms and regulations, particularly in the U.S. and the EU.
Key Trends Explored:
- Genericdrug
Markets and Markets, Nov 2011, Pages: 129
Therapy Drugs To Drive The Market For Lung Cancer
3.5.1.2 Rising Incidence Of Lung Cancer To Drive The Market For Drugs
3.5.1.3 Genericization Of Major Drugs To Slow Down The Pace Of The Market
3
Frost & Sullivan, Dec 2006, Pages: 51
a detailed analysis of various issues affecting pricing and reimbursement decisions of generics in Europe. The study includes an overview of cost-containment measures such as reference pricing, parallel trade
Espicom Business Intelligence Ltd, April 2007, Pages: 190
Market Projections, 2007-2012
Generics & Total Pharmaceutical Market Projections, 2007-2012 (US$ billion)
Original Drugs with Patent Close to Expiry, 2006-2013
SWOT Analysis of the Market of Generic Medicines, 2007
Business Insights, April 2008, Pages: 147
developments with this new report...
Top five reasons to order your copy today
- Examine the latest developments in US and European drug approval processes with this report’s detailed analysis of the key
GBI Research, May 2012, Pages: 66
Impact on Pricing
6 Drug Price Cuts in Top Five Countries of Europe – Geographical Landscape
6.1 The UK
6.1.1 Macroeconomic Factors (PEST Analysis)
6.1.2 Healthcare System in Country
6.1.3 Total
MarketLine, Aug 2010, Pages: 242
IN SPAIN
MARKET OVERVIEW
MARKET VALUE
MARKET SEGMENTATION I
MARKET SEGMENTATION II
FIVE FORCES ANALYSIS
MARKET FORECASTS
MACROECONOMIC INDICATORS
GENERICS IN THE UNITED KINGDOM
MARKET OVERVIEW
GBI Research, March 2012, Pages: 57
.4 Rationale for Drug Use in the Healthcare Facilities
4 Pricing and Reimbursement in India- Overview of Pharmaceutical Regulations in India
4.1 PEST Analysis of the Pharmaceutical Industry in India
4
